

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Efgartigimod for treating chronic inflammatory demyelinating polyneuropathy [ID6409]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

No

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?

Yes, it was highlighted that many people with CIDP are considered disabled, so the impact on disability, especially in terms of access to a treatment that may reduce disability, should be considered. They mentioned that most people with CIDP are generally older, so age may be a factor to consider in any decision making. The committee noted that its current recommendation applied to all groups.

It was also highlighted some people may decline blood products because of religion or belief. The committee concluded that the company's positioning of efgartigimod was for people already having immunoglobulin, so it cannot consider this population in its decision making.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No other potential equality issues were identified by the committee.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

Not applicable

7. Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

Yes, section 3.25 of the draft guidance.

Approved by Associate Director (name): Richard Diaz

Date: 16 April 2026